301 related articles for article (PubMed ID: 32113080)
1. Current management of stage IV nasopharyngeal carcinoma without distant metastasis.
Ng WT; Corry J; Langendijk JA; Lee AWM; Mäkitie A; Mendenhall WM; Rinaldo A; Rodrigo JP; Saba NF; Smee R; Strojan P; Suárez C; Vermorken JB; Ferlito A
Cancer Treat Rev; 2020 Apr; 85():101995. PubMed ID: 32113080
[TBL] [Abstract][Full Text] [Related]
2. Concurrent chemoradiotherapy by simultaneously integrated boost volumetric-modulated arc therapy for nasopharyngeal carcinoma-toxicity/quality of life and survival.
Fang FM; Huang TL; Lin YH; Chien CY; Chuang HC; Luo SD; Lin HC; Lin YT; Li SH; Liao KC; Tsai WL
Head Neck; 2019 May; 41(5):1282-1289. PubMed ID: 30548091
[TBL] [Abstract][Full Text] [Related]
3. Proton therapy following induction chemotherapy for pediatric and adolescent nasopharyngeal carcinoma.
Uezono H; Indelicato DJ; Rotondo RL; Sandler ES; Katzenstein HM; Dagan R; Mendenhall WM; Mailhot Vega R; Brennan BM; Bradley JA
Pediatr Blood Cancer; 2019 Dec; 66(12):e27990. PubMed ID: 31524334
[TBL] [Abstract][Full Text] [Related]
4. Locoregional Control and Mild Late Toxicity After Reducing Target Volumes and Radiation Doses in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma Treated With Induction Chemotherapy (IC) Followed by Concurrent Chemoradiotherapy: 10-Year Results of a Phase 2 Study.
Zhao C; Miao JJ; Hua YJ; Wang L; Han F; Lu LX; Xiao WW; Wu HJ; Zhu MY; Huang SM; Lin CG; Deng XW; Xie CH
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):836-844. PubMed ID: 30954521
[TBL] [Abstract][Full Text] [Related]
5. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma.
Ng WT; Ngan RKC; Kwong DLW; Tung SY; Yuen KT; Kam MKM; Sze HCK; Yiu HHY; Chan LLK; Lung ML; Lee AWM
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):630-638. PubMed ID: 29413277
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
Setakornnukul J; Thephamongkhol K
BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
Li PJ; Mo HY; Luo DH; Hu WH; Jin T
Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
[TBL] [Abstract][Full Text] [Related]
8. Effects of induction docetaxel, platinum, and fluorouracil chemotherapy in patients with stage III or IVA/B nasopharyngeal cancer treated with concurrent chemoradiation therapy: Final results of 2 parallel phase 2 clinical trials.
Kong L; Zhang Y; Hu C; Guo Y; Lu JJ
Cancer; 2017 Jun; 123(12):2258-2267. PubMed ID: 28192641
[TBL] [Abstract][Full Text] [Related]
9. IMRT combined with concurrent chemotherapy plus adjuvant chemotherapy versus IMRT combined with concurrent chemotherapy alone in patients with nasopharyngeal carcinoma.
Zhong Q; Zhu X; Li L; Qu S; Liang Z; Zeng F; Pan X
Oncotarget; 2017 Jun; 8(24):39683-39694. PubMed ID: 28147309
[TBL] [Abstract][Full Text] [Related]
10. The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis.
Song JH; Wu HG; Keam BS; Hah JH; Ahn YC; Oh D; Noh JM; Park HJ; Lee CG; Keum KC; Cha J; Cho KH; Moon SH; Kim JY; Chung WK; Oh YT; Kim WT; Cho MJ; Kay CS; Kim YS
Cancer Res Treat; 2016 Jul; 48(3):917-27. PubMed ID: 26727716
[TBL] [Abstract][Full Text] [Related]
11. Anti-EGFR targeted therapy delivered before versus during radiotherapy in locoregionally advanced nasopharyngeal carcinoma: a big-data, intelligence platform-based analysis.
Peng H; Tang LL; Liu X; Chen L; Li WF; Mao YP; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J
BMC Cancer; 2018 Mar; 18(1):323. PubMed ID: 29580204
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy for the treatment of locoregionally advanced nasopharyngeal carcinoma: a retrospective controlled study.
Qiu WZ; Huang PY; Shi JL; Xia HQ; Zhao C; Cao KJ
Chin J Cancer; 2016 Jan; 35():2. PubMed ID: 26739148
[TBL] [Abstract][Full Text] [Related]
13. Combined chemoradiation vs radiation therapy alone in stage-II nasopharyngeal carcinoma: A meta-analysis of the published literature.
Wang S; Li S; Shen L
Curr Probl Cancer; 2018; 42(3):302-318. PubMed ID: 29759802
[TBL] [Abstract][Full Text] [Related]
14. Adapted strategy to tumor response in childhood nasopharyngeal carcinoma: the French experience.
Jouin A; Helfre S; Bolle S; Claude L; Laprie A; Bogart E; Vigneron C; Potet H; Ducassou A; Claren A; Riet FG; Castex MP; Faure-Conter C; Fresneau B; Defachelles AS; Orbach D
Strahlenther Onkol; 2019 Jun; 195(6):504-516. PubMed ID: 30963203
[TBL] [Abstract][Full Text] [Related]
15. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
[TBL] [Abstract][Full Text] [Related]
16. PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: Substudy of a randomized phase III trial.
Cao C; Wei Q; Tang X; Jia Y; Sun X; Li W; Hu Q; Chen X
Head Neck; 2019 May; 41(5):1427-1433. PubMed ID: 30582240
[TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in stage III-IVb nasopharyngeal carcinoma patients with Epstein-Barr virus DNA ≥4000 copies/ml: a matched study.
Guo SS; Tang LQ; Chen QY; Zhang L; Liu LT; Guo L; Mo HY; Luo DH; Huang PY; Xiang YQ; Sun R; Chen MY; Wang L; Lv X; Zhao C; Guo X; Cao KJ; Qian CN; Zeng MS; Bei JX; Hong MH; Shao JY; Sun Y; Ma J; Mai HQ
Oncotarget; 2016 May; 7(20):29739-48. PubMed ID: 27105538
[TBL] [Abstract][Full Text] [Related]
18. A novel scoring model to predict benefit of additional induction chemotherapy to concurrent chemoradiotherapy in stage II-IVa nasopharyngeal carcinoma.
Peng L; Chen YP; Xu C; Tang LL; Chen L; Lin AH; Liu X; Sun Y; Ma J
Oral Oncol; 2018 Nov; 86():258-265. PubMed ID: 30409310
[TBL] [Abstract][Full Text] [Related]
19. Home enteral nutrition may prevent myelosuppression of patients with nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.
Li X; Zhou J; Chu C; You Q; Zhong R; Rao Z; Hu W
Head Neck; 2019 Oct; 41(10):3525-3534. PubMed ID: 31301097
[TBL] [Abstract][Full Text] [Related]
20. Examining prognostic factors and patterns of failure in nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy: impact on future clinical trials.
Cheng SH; Yen KL; Jian JJ; Tsai SY; Chu NM; Leu SY; Chan KY; Tan TD; Cheng JC; Hsieh CY; Huang AT
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):717-26. PubMed ID: 11395240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
